MX2021009275A - Moleculas de union especificas. - Google Patents
Moleculas de union especificas.Info
- Publication number
- MX2021009275A MX2021009275A MX2021009275A MX2021009275A MX2021009275A MX 2021009275 A MX2021009275 A MX 2021009275A MX 2021009275 A MX2021009275 A MX 2021009275A MX 2021009275 A MX2021009275 A MX 2021009275A MX 2021009275 A MX2021009275 A MX 2021009275A
- Authority
- MX
- Mexico
- Prior art keywords
- domain
- specific binding
- binding molecules
- vlcdr1
- vlcdr2
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/33—Antibodies; T-cell engagers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1901305.1A GB201901305D0 (en) | 2019-01-30 | 2019-01-30 | Specific binding molecules |
| PCT/EP2020/052315 WO2020157210A1 (en) | 2019-01-30 | 2020-01-30 | Cd3-specific binding molecules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021009275A true MX2021009275A (es) | 2021-08-16 |
Family
ID=65997940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021009275A MX2021009275A (es) | 2019-01-30 | 2020-01-30 | Moleculas de union especificas. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12590152B2 (https=) |
| EP (1) | EP3917959A1 (https=) |
| JP (1) | JP7530904B2 (https=) |
| KR (1) | KR20210121141A (https=) |
| CN (1) | CN113728005B (https=) |
| AU (1) | AU2020215776A1 (https=) |
| BR (1) | BR112021014963A2 (https=) |
| CA (1) | CA3127144A1 (https=) |
| GB (1) | GB201901305D0 (https=) |
| IL (1) | IL284926B2 (https=) |
| MX (1) | MX2021009275A (https=) |
| WO (1) | WO2020157210A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12162940B2 (en) | 2021-05-05 | 2024-12-10 | Immatics Biotechnologies Gmbh | BMA031 antigen binding polypeptides |
| CN115724988B (zh) * | 2021-08-26 | 2023-11-17 | 瑅安生物医药（杭州）有限公司 | 一种接近天然分子的多肽融合分子 |
| KR20240149435A (ko) | 2022-02-20 | 2024-10-14 | 이뮤노코어 리미티드 | Hiv 특이적 결합 분자 |
| MX2025001960A (es) | 2022-08-18 | 2025-05-02 | Immunocore Ltd | Moléculas de unión multidominio |
| US12134647B2 (en) | 2023-01-06 | 2024-11-05 | Immunocore Limited | Binding molecules |
| US12195534B2 (en) | 2023-01-06 | 2025-01-14 | Immunocore Limited | Binding molecules |
| TW202519257A (zh) * | 2023-08-01 | 2025-05-16 | 英商英美偌科有限公司 | 治療皮膚黑色素瘤之方法 |
| WO2025050404A1 (zh) * | 2023-09-08 | 2025-03-13 | 成都维瑾柏鳌生物医药科技有限公司 | 一种药物组合物及其应用 |
| GB202320012D0 (en) | 2023-12-22 | 2024-02-07 | Immunocore Ltd | Bispecific molecules |
| GB2641580A (en) | 2024-06-07 | 2025-12-10 | T Therapeutics Ltd | Tumour-transforming multispecific proteins |
| WO2026078231A1 (en) | 2024-10-11 | 2026-04-16 | T-Therapeutics Limited | Soluble non-aggregating immune ligand |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US36676A (en) | 1862-10-14 | Improvement in grain-cleaners | ||
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| AU7757581A (en) | 1980-11-19 | 1982-05-27 | United Energy Technologies Inc. | Enhanced surface tubing |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| JPS5855530Y2 (ja) | 1981-06-15 | 1983-12-20 | 松下電工株式会社 | 照明器具を有する天井 |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
| DE3218121A1 (de) | 1982-05-14 | 1983-11-17 | Leskovar, Peter, Dr.-Ing., 8000 München | Arzneimittel zur tumorbehandlung |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4630115A (en) | 1983-05-09 | 1986-12-16 | The General Electric Company, P.L.C. | Cathode ray tube display device |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| DE69232137T2 (de) | 1991-11-25 | 2002-05-29 | Enzon Inc | Multivalente antigen-bindende proteine |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| AU6685698A (en) | 1997-03-07 | 1998-09-22 | Sunol Molecular Corporation | Fusion proteins comprising bacteriophage coat protein and a single-chain t cell receptor |
| WO1999018129A1 (en) | 1997-10-02 | 1999-04-15 | Sunol Molecular Corporation | Soluble single-chain t-cell receptor proteins |
| WO2001062908A2 (en) | 2000-02-22 | 2001-08-30 | Ahuva Nissim | Chimeric and tcr phage display libraries, chimeric and tcr reagents and methods of use thereof |
| CN101289511A (zh) | 2000-04-11 | 2008-10-22 | 杰南技术公司 | 多价抗体及其应用 |
| AU2002321581C1 (en) | 2001-08-31 | 2008-09-18 | Adaptimmune Limited | Soluble T cell receptor |
| AU2003271904B2 (en) | 2002-10-09 | 2009-03-05 | Adaptimmune Limited | Single chain recombinant T cell receptors |
| US8361794B2 (en) | 2004-06-29 | 2013-01-29 | Immunocore Limited | Cells expressing a modified T cell receptor |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| GB0908613D0 (en) * | 2009-05-20 | 2009-06-24 | Immunocore Ltd | T Cell Reseptors |
| GB0911566D0 (en) | 2009-07-03 | 2009-08-12 | Immunocore Ltd | T cell receptors |
| WO2014012085A2 (en) | 2012-07-13 | 2014-01-16 | Zymeworks Inc. | Bispecific asymmetric heterodimers comprising anti-cd3 constructs |
| UA129760C2 (uk) * | 2013-12-17 | 2025-07-30 | Дженентек, Інк. | Анти-cd3 антитіло та спосіб його застосування |
| US9209965B2 (en) | 2014-01-14 | 2015-12-08 | Microsemi Semiconductor Ulc | Network interface with clock recovery module on line card |
| GB201522592D0 (en) | 2015-12-22 | 2016-02-03 | Immunocore Ltd | T cell receptors |
| PL3440105T3 (pl) | 2016-04-08 | 2022-08-29 | Immunocore Limited | Receptory komórek t |
| GB201709866D0 (en) * | 2017-06-20 | 2017-08-02 | Immunocore Ltd | T cell receptors |
| GB201915282D0 (en) * | 2019-10-22 | 2019-12-04 | Immunocore Ltd | Specific binding molecules |
| GB202006629D0 (en) * | 2020-05-05 | 2020-06-17 | Immunocore Ltd | Specific binding molecules |
| US12103971B2 (en) * | 2022-02-20 | 2024-10-01 | Immunocore Limited | HIV specific binding molecules |
| CA3265218A1 (en) * | 2022-08-18 | 2024-02-22 | Immunocore Ltd | MAGE A4 SPECIFIC T LYMPHOCYTE RECEPTOR FUSION PROTEINS |
| US12195534B2 (en) * | 2023-01-06 | 2025-01-14 | Immunocore Limited | Binding molecules |
| US12134647B2 (en) * | 2023-01-06 | 2024-11-05 | Immunocore Limited | Binding molecules |
-
2019
- 2019-01-30 GB GBGB1901305.1A patent/GB201901305D0/en not_active Ceased
-
2020
- 2020-01-30 CA CA3127144A patent/CA3127144A1/en active Pending
- 2020-01-30 AU AU2020215776A patent/AU2020215776A1/en active Pending
- 2020-01-30 WO PCT/EP2020/052315 patent/WO2020157210A1/en not_active Ceased
- 2020-01-30 BR BR112021014963-5A patent/BR112021014963A2/pt unknown
- 2020-01-30 MX MX2021009275A patent/MX2021009275A/es unknown
- 2020-01-30 CN CN202080012045.4A patent/CN113728005B/zh active Active
- 2020-01-30 KR KR1020217027112A patent/KR20210121141A/ko active Pending
- 2020-01-30 US US17/427,592 patent/US12590152B2/en active Active
- 2020-01-30 EP EP20703192.3A patent/EP3917959A1/en active Pending
- 2020-01-30 IL IL284926A patent/IL284926B2/en unknown
- 2020-01-30 JP JP2021544406A patent/JP7530904B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021014963A2 (pt) | 2021-09-28 |
| EP3917959A1 (en) | 2021-12-08 |
| JP7530904B2 (ja) | 2024-08-08 |
| GB201901305D0 (en) | 2019-03-20 |
| CA3127144A1 (en) | 2020-08-06 |
| WO2020157210A1 (en) | 2020-08-06 |
| IL284926A (en) | 2021-09-30 |
| KR20210121141A (ko) | 2021-10-07 |
| CN113728005B (zh) | 2025-02-21 |
| AU2020215776A1 (en) | 2021-09-09 |
| US20220119527A1 (en) | 2022-04-21 |
| CN113728005A (zh) | 2021-11-30 |
| US12590152B2 (en) | 2026-03-31 |
| IL284926B1 (en) | 2025-11-01 |
| JP2022523507A (ja) | 2022-04-25 |
| IL284926B2 (en) | 2026-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021009275A (es) | Moleculas de union especificas. | |
| PE20200717A1 (es) | Moleculas de anticuerpo que se unen a cd73 y usos de las mismas | |
| PE20211767A1 (es) | Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos anti-hla-g y metodos de uso de anticuerpos anti-hla-g | |
| RU2014100111A (ru) | МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕСЯ С Psl Pseudomonas, И ПУТИ ИХ ПРИМЕНЕНИЯ | |
| PE20211091A1 (es) | Proteina de union al antigeno anti-steap1 | |
| FI4249515T3 (fi) | Humanisoituja tai kimeerisiä CD3-vasta-aineita | |
| ECSP16070447A (es) | Moleculas de anticuerpo para tim-3 y sus usos | |
| HRP20201517T1 (hr) | Anti-cd3 protutijela, anti-cd123 protutijela i bispecifična protutijela koja se specifično vežu na cd3 i/ili cd123 | |
| NZ607510A (en) | Anti-il-1 beta antibodies and methods of use | |
| CL2015001895A1 (es) | Anticuerpos que se unen al tl1a y sus usos | |
| NZ721678A (en) | Antibody molecules to pd-1 and uses thereof | |
| AR111361A1 (es) | Anticuerpos biespecíficos de unión específica a pd1 y lag3 | |
| AR085624A2 (es) | Anticuerpos de p-caderina | |
| PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
| PE20161431A1 (es) | Anticuerpos biespecificos que se unen a cd38 y cd3 | |
| EA201691779A1 (ru) | Антитела, специфические к рецептору инсулиноподобного фактора роста 1, и их применения | |
| EP4356972A3 (en) | Anti-annexin a2 monoclonal antibodies | |
| PE20171324A1 (es) | Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales | |
| JP2016514463A5 (https=) | ||
| PE20251579A1 (es) | Anticuerpos especificos para cd70 y sus usos | |
| PH12021551627A1 (en) | Conjugate comprising ligand and ceacam5 antibody fab fragment | |
| EA201100527A1 (ru) | Биологические продукты | |
| EA201200526A1 (ru) | Поливалентные антитела, стабилизированные дисульфидом | |
| MX369276B (es) | Agentes para tratamiento de enfermedades cancerosas que expresan claudina. | |
| BR112019007272A2 (pt) | anticorpos anti-ceacam6 e métodos de utilização |